MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
Vivos Therapeutics Operating Income 2011-2026 | VVOS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Vivos Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.2 M | -17.3 M | -25 M | -20.4 M | -12 M | -10.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.6 M | -25 M | -16.1 M |
Quarterly Operating Income Vivos Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.73 M | -4.86 M | -3.92 M | - | -2.64 M | -1.94 M | -3.78 M | - | -3.64 M | -4.52 M | -5 M | - | -5.41 M | -6.96 M | -6.82 M | - | -5.5 M | -4.06 M | -3.41 M | - | -1.82 M | -1.42 M | -2.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.42 M | -6.96 M | -4.06 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 28.6 | -1.92 % | $ 1.32 B | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 12.19 | -3.02 % | $ 1.83 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 36.62 | -4.9 % | $ 5.46 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 8.63 | 2.92 % | $ 620 M |  Israel |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 9.51 | -0.94 % | $ 1.29 B | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.0 | -1.56 % | $ 203 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 40.21 | -2.9 % | $ 1.25 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.21 | -0.94 % | $ 157 M |  France |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.16 | -3.07 % | $ 109 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.48 | -0.48 % | $ 121 M | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.49 | -2.39 % | $ 50.4 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.82 | 1.35 % | $ 44.6 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 173.34 | -1.29 % | $ 13 B | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 3.65 | -2.93 % | $ 773 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
8.05 B | $ 109.92 | -0.95 % | $ 191 B | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 98.53 | -1.57 % | $ 1.25 B | USA |
 |
Inogen
INGN
|
-30.2 M | $ 6.46 | -1.37 % | $ 172 M | USA |
 |
InMode Ltd.
INMD
|
85.4 M | $ 13.26 | -1.45 % | $ 857 M | Israel |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 71.46 | -2.09 % | $ 106 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 18.05 | 1.29 % | $ 423 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.24 | -10.14 % | $ 20 M | USA |
 |
Pulmonx Corporation
LUNG
|
-57.7 M | $ 2.03 | 25.78 % | $ 79.4 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.17 | -3.55 % | $ 1.32 M | USA |
 |
Medtronic PLC
MDT
|
5.96 B | $ 90.96 | -2.2 % | $ 117 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 82.03 | -2.21 % | $ 48 B | USA |